Scientific Program
Bradykinin Symposium
The detailed scientific program is currently being set up and will be available in its preliminary version shortly.
by March 2026
Thursday, 03 September 2026
Registration from 11:00 – 12:00
Welcome 12:00
Program TBA 12:00 – 17:00
Scientific Dinner 18:00 – 22:30
Friday, 04 September 2026
Registration from 08:00 – 08:15
Program TBA from 08:15 – 18:00
Thursday, 5 September 2024
11.15-12.00
Registration and Lunch
12.00-12.15
Welcome
Markus Magerl, Berlin (Germany) | Thomas Renné, Hamburg (Germany) | Michael Bader, Berlin (Germany)
Session I: Bradykinin basics
12.15-13.00
Vascular Homeostasis over the Lifespan
Hellmut Augustin, Heidelberg (Germany)
13.00-13.30
AAE and HAE: two sides of the same coin or not?
Danny Cohn, Amsterdam (The Netherlands)
13.30-13.55
Coffee Break
13.55-14.25
Role of the kallikrein-kinin system in post-transplant focal segmental glomerulosclerosis recurrence
Joao Pesquero, Sao Paulo (Brazil)
14.25-15.05
New insights into the contact activation system
Allen Kaplan, Charleston (USA)
15.05-15.15
OP.01 | CRISPR-Based Gene Editing of KLKB1 Resulted in Long-Term Plasma Kallikrein Protein Reduction and Decreased Attack Rate in Patients With Hereditary Angioedema: Updated Results From a Phase 1 Study
Hilary Longhurst, Auckland (New Zealand)
15.15-15.25
OP.02 | Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat
Jolanta Skarbaliene, Zug (Switzerland)
15.25-15.35
OP.03 | Molecular Genetics of Fletcher and Fitzgerald Traits
Anke Adenaeuer, Mainz (Germany)
15.35-15.50
Coffee Break
Session III: Kinin Receptors
15.50-16.20
Bradykinin receptors in skin
Daniela de Almeida Cabrini, Paraná (Brazil
16.20-16.50
Kinin B1 receptor in inflammatory arthritis
David A. Fox, Ann Arbor (USA)
16.50-17.00
OP.04 | Elaboration of possible targets in bradykinin-mediated endothelial barrier disruption
Raphael Möhrle, Ulm (Germany)
17.00-17.10
OP.05| B1KO mice exhibits low expression of adipogenesis markers
Gabriel de Melo Arthur, Sao Paulo (Brazil)
The E.K. Frey – E. Werle Award Ceremony
17.15-17.25
Laudation for the Gold Medal Winner Werner Müller-Esterl, Frankfurt (Germany)
17.25-17.45
Disease Patterns in the FXII & Kallikrein/Kinin System Alvin Schmaier, Cleveland OH (USA)
17.50-18:00
Awarding of the Promotion Price
18.00-22.30
Scientific Dinner
Friday, 6 September 2024
08.00-08.15
Coffee and Welcome
08.15-08.20
Summary day 1
Markus Magerl, Berlin (Germany) | Thomas Renné, Hamburg (Germany) | Michael Bader, Berlin (Germany)
Session IV: The contact system – in disease states I
08.20-08.50
An update on C1INH regulation
Steven Philip Grover, Chapel Hill (USA)
08.50-09.20
The kallikrein kinin system in bacterial infections
Sonja Oehmcke, Rostock (Germany)
09.20-09.30
OP.06 | Delayed On-demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported by Italian Patients
Mauro Cancian, Padova (Italy)
09.30-09.40
OP.07 | Being attack-free with garadacimab impacts quality of life in HAE
Petra Staubach, Mainz (Germany)
09.40-09.50
OP.08 | Patient-Reported Outcomes With Lanadelumab by Hereditary Angioedema Activity: EMPOWER/ENABLE Analysis
Andrea Zanichelli, Milan (Italy)
09.50-10.20
Coffee Break
Session V: Kinin activities and regulations
10.20-10.50
Polyphosphates: activators of the contact system
Reiner Mailer, Hamburg (Germany)
10.50-11.20
Molecular Dambusters: What is behind hyperpermeability in bradykinin-mediated angioedema?
Márta L Debreczeni, Budapest (Hungary)
11.20-11.30
OP.09 | Novel Rezolute Plasma Kallikrein Inhibitors Prevent Edema in Animal Models
Jeffrey Breit, Bend (USA)
11.30-11.40
OP.10 | Traffic-generated nanoparticles are strong activators of the human kallikrein/kinin system
Karin Fromell, Uppsala (Sweden)
11.40-11.50
OP.11 | Heme binds to and activates factor XII leading to bradykinin release during hemolysis
Alexandra Gerogianni, Lund (Sweden)
11.50-12.00
OP.12 | A specific, sensitivity assay measuring patient sample plasma kallikrein activity
Daniel Lee, Cambridge (USA)
12.00-12.20
Coffee Break
Session VI: The contact system – in disease states II
12.20-12.50
Current status – modern new therapies
Timothy Craig, Hershey, PA (USA)
12.50-13.00
OP.13 | The Kallikrein-kinin system is an early biomarker of SARS-CoV-2 infection
Barbro Persson, Uppsala (Sweden)
13.00-13.10
OP.14 | KONFIDENT-S Interim Analysis: Sebetralstat for Hereditary Angioedema Attacks Including Laryngeal
Henriette Farkas, Budapest (Hungary)
13.10-13.20
OP.15 | Impact of Factor XII, Prekallikrein and C1-Inhibitor in Renal Fibrosis
Rodrigo Silva-Aguiar, Cleveland (USA)
13.20-13.30
OP.16 | Pooled Sebetralstat Placebo-controlled Safety for On-demand Treatment of Hereditary Angioedema
Emel Aygören-Pürsün, Frankfurt (Germany)
13.30-13.40
OP.17 | Lanadelumab Effectiveness and Safety by Disease Activity: EMPOWER/ENABLE Pooled Analysis
Andrea Zanichelli, Milan (Italy)
13.40-14.30
Lunch
Session VII: Hereditary angioedema
14.30-14.55
Current and prospective targets of pharmacologic therapies
Lauré M Fijen, Amsterdam (The Netherlands)
14.55-15.05
OP.18 | Reduction in Plasma Kallikrein by CRISPR-Based Gene Editing of KLKB1 Did Not Alter Coagulation in the Phase 1 Study of Patients With Hereditary Angioedema
Remy S Petersen, Amsterdam (The Netherlands)
15.05-15.15
OP.19 | Prophylactic Treatment With Deucrictibant Improves HAE Disease Control and HRQoL
Markus Magerl, Berlin (Germany)
15.15-15.25
OP.20 | Rare and complexes connective tissue diseases in patients with C1-inhibitor deficiency Hereditary Angioedema: first evidence on prevalence and distribution from a large Italian cohort study
Riccardo Senter, Padova (Italy)
15.25-15.35
OP.21 | Angioedema due to familial acquired C1-inhibitor deficiency
Ramon Lleonart Bellfill, Barcelona (Spain)
15.35-16.15
Poster Session
Session VIII: HAE Worldwide
16.15-16.40
News from the world of angioedema
Anete S. Grumach, Santo André (Brazil)
16.40-16.50
OP.22 | Screening Programme Outreach for Testing Hereditary Angioedema (SPOT-HAE): Validation and Utilizing Dried Blood Spot for Family Screening
Jane C Y Wong, Hong Kong (China)
16.50-17.00
OP.23 | A physician-based Brazilian Registry for Hereditary Angioedema: first 704 patients
José Eduardo Seneda Lemos, Sao Paulo (Brazil)
17.00-17.10
OP.24 | Psychometric analysis of AE-QoL from HAE subsamples in observational studies
Thomas Buttgereit, Berlin (Germany)
17.10-17.25
Conclusion: What did we hear? What take we home?
Markus Magerl, Berlin (Germany)
17.25-17.40
Closing remarks
Markus Magerl, Berlin (Germany) | Thomas Renné, Hamburg (Germany) | Michael Bader, Berlin (Germany)
If you need child care, please contact our professional congress organiser via bradykinin@remember-management.de.
